Fundamental Analysis of GLYCOMIMETICS INC(NASDAQ:GLYC) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to GLYC. GLYC was compared to 588 industry peers in the Biotechnology industry. The financial health of GLYC is average, but there are quite some concerns on its profitability. GLYC has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year GLYC has reported negative net income.

In the past year GLYC has reported a negative cash flow from operations.

In the past 5 years GLYC always reported negative net income.

GLYC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -81.42%, GLYC is not doing good in the industry: 71.84% of the companies in the same industry are doing better.

GLYC's Return On Equity of -96.05% is in line compared to the rest of the industry. GLYC outperforms 45.90% of its industry peers.

		Industry Rank	Sector Rank
ROA	-81.42%
ROE	-96.05%
ROIC	N/A

ROA(3y)-79.61%

ROA(5y)-61.8%

ROE(3y)-94.21%

ROE(5y)-71.99%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GLYC so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GLYC does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, GLYC has more shares outstanding

Compared to 5 years ago, GLYC has more shares outstanding

GLYC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

GLYC has an Altman-Z score of -6.91. This is a bad value and indicates that GLYC is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of GLYC (-6.91) is worse than 70.14% of its industry peers.

GLYC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-6.91

ROIC/WACCN/A

WACC9.27%

2.3 Liquidity

A Current Ratio of 6.41 indicates that GLYC has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 6.41, GLYC is in the better half of the industry, outperforming 65.02% of the companies in the same industry.

GLYC has a Quick Ratio of 6.41. This indicates that GLYC is financially healthy and has no problem in meeting its short term obligations.

GLYC has a Quick ratio of 6.41. This is in the better half of the industry: GLYC outperforms 65.53% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	6.41
Quick Ratio	6.41

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.09% over the past year.

Looking at the last year, GLYC shows a very negative growth in Revenue. The Revenue has decreased by -87.50% in the last year.

Measured over the past years, GLYC shows a very negative growth in Revenue. The Revenue has been decreasing by -90.05% on average per year.

EPS 1Y (TTM)34.09%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q26.32%

Revenue 1Y (TTM)-87.5%

Revenue growth 3Y-90.05%

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

GLYC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.56% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-7.28%

EPS Next 2Y9.74%

EPS Next 3Y41.88%

EPS Next 5Y51.56%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

GLYC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year GLYC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as GLYC's earnings are expected to grow with 41.88% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y9.74%

EPS Next 3Y41.88%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for GLYC!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GLYCOMIMETICS INC

NASDAQ:GLYC (5/2/2024, 10:58:45 AM)

1.725

+0.1 (+6.48%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap111.18M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-81.42%
ROE	-96.05%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	6.41
Quick Ratio	6.41
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)34.09%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-7.28%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-87.5%

Revenue growth 3Y-90.05%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

GLYCOMIMETICS INC (GLYC)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens